Contamination of liposomal bupivacaine during multi-dose usage in a clinical setting evaluated by culture and PCR

通过培养和 PCR 评估临床环境中多剂量使用过程中脂质体布比卡因的污染情况

阅读:6
作者:Rachel L Melvin, Jing Wu, Brad S Bennett, Sara D Lawhon, Amy Savarino, Artem S Rogovskyy, Kelley M Thieman Mankin

Discussion

Results support the aseptic handling protocol described in this article is successful in preventing detectable bacterial and fungal contamination of liposomal bupivacaine vials for up to 7 individual punctures and vials open for up to 5 days.

Methods

The first (Control) and last (Sample B) 0.5 mL from each vial were collected and submitted for bacterial and fungal PCR, anaerobic and aerobic bacterial culture, and opportunistic fungal culture.

Results

All 40 bacterial cultures yielded no growth; Bacterial or fungal DNA was identified in 19 samples (50%). Of the 19 samples in which bacterial or fungal DNA was identified, 10 (52.6%) were from Control, and 9 (47.4%) were from Sample B. PCR does not appear to be useful in detecting bacterial or fungal contamination from liposomal bupivacaine.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。